Liver Injury from Herbs and “Dietary Supplements”: Highlights of a Literature Review from 2015 to 2017

  • Rolf Teschke
  • Axel Eickhoff
  • Albrecht Wolff
  • Tran Dang Xuan
Drug-induced Liver Injury (X Ma, Section Editor)
  • 5 Downloads
Part of the following topical collections:
  1. Topical Collection on Drug-induced Liver Injury

Abstract

Purpose of the Review

To present highlights of recent liver injury from herbs and “dietary supplements,” based on a literature review from 2015 to 2017.

Recent findings

Challenging are quality issues of herb and dietary supplements (HDS) products, influenced by the circadian clock system in plants that controls many important metabolic pathways including photosynthesis and molecular processes of gene expression. Important also is plant stress, caused by pathogen attacks, heavy UV radiation, draft, soil contamination by salts or heavy metals, involving oxidative stress through generation of free radicals including reactive oxygen species (ROS), damaging the plant’s integrity. Finally, expectations are high if physicians publish case reports of HDS liver injury using the Roussel Uclaf Causality Assessment Method (RUCAM), but intentional overscoring of causality gradings must be resisted. In critical situations, reevaluation of original case data was a good approach clarifying divergencies.

Summary

Plant stress impairs the quality of herbs, requiring better understanding of plant physiology, and clinical liver injury cases need better causality assessment using RUCAM.

Keywords

Herb-induced liver injury Herbal and dietary supplement liver injury Herbal product quality Causality assessment RUCAM Roussel Uclaf Causality Assessment Method Plant physiology plant chronobiology 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors received no financial support for writing this commissioned manuscript. No conflicts of interest have been declared in relation to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

  1. 1.
    Shahbaz O, Mahajan S, Lewis JH. Highlights of drug- and herb-induced liver injury in the literature from 2016: how best to translate new information into clinical practice? Expert Opin Drug Metab Toxicol 2017; 13(9):935–951. Available at:  https://doi.org/10.1080/17425255.2017.1362391
  2. 2.
    Sarges P, Steinberg JM, Lewis JH. Drug-induced liver injury: highlights from a review of the 2015 literature. Drug Saf. 2016;39(6):561–75.  https://doi.org/10.1007/s4026401604278.CrossRefGoogle Scholar
  3. 3.
    Teschke R, Andrade RJ. Editorial. Special issue “drug, herb, and dietary supplement hepatotoxicity”. Int J Mol Sci. 2016;17(9):1488.  https://doi.org/10.3390/ijms17091488. Available at: http://www.mdpi.com/journal/ijms/special_issues/Hepatotoxicity. Accessed 22.10.17.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci. 2016;17(1):14.  https://doi.org/10.3390/ijms17010014.Google Scholar
  5. 5.
    Frenzel C, Teschke R. Herbal hepatotoxicity: clinical characteristics and listing compilation. Int J Mol Sci. 2016;17(5):588.  https://doi.org/10.3390/ijms17050588.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Valdivia-Correa B, Gómez-Gutiérrez C, Uribe M, Méndez-Sánchez N. Herbal medicine in Mexico: a cause of hepatotoxicity. A critical review. Int J Mol Sci. 2016;17(2):235.  https://doi.org/10.3390/ijms17020235.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Douros A, Bronder E, Andersohn F, Klimpel A, Kreutz R, Garbe E, et al. Herb-induced liver injury in the Berlin Case-Control Surveillance Study. Int J Mol Sci. 2016;17(1):114.  https://doi.org/10.3390/ijms17010114.CrossRefPubMedCentralGoogle Scholar
  8. 8.
    Pantano F, Tittarelli R, Mannocchi G, Zaami S, Ricci S, Giorgetti R, et al. Hepatotoxicity induced by “the 3Ks”: Kava, Kratom and Khat. Int J Mol Sci. 2016;17(4):580.  https://doi.org/10.3390/ijms17040580.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    García-Cortés M, Robles-Díaz M, Ortega-Alonso A, Medina-Caliz I, Andrade RJ. Hepatotoxicity by dietary supplements: a tabular listing and clinical characteristics. Int J Mol Sci. 2016;17(4):537.  https://doi.org/10.3390/ijms17040537.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Teschke R, Eickhoff A. The Honolulu liver disease cluster at the medical center: its mysteries and challenges. Int J Mol Sci. 2016;17(4):476.  https://doi.org/10.3390/ijms17040476.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Avigan MI, Mozersky RP, Seeff LB. Scientific and regulatory perspectives in herbal and dietary supplement associated hepatotoxicity in the United States. Int J Mol Sci. 2016;17(3):331.  https://doi.org/10.3390/ijms17030331.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Dakhiya Y, Hussien D, Fridman E, Kiflawi M, Green R. Correlations between circadian rhythms and growth in challenging environments. Plant Physiol. 2017;173(3):1724–34.  https://doi.org/10.1104/pp.17.00057.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Xuan TD, Khanh TD, Khang DT, Quan NT, Elzaawely AA. Changes in chemical composition, total phenolics and antioxidant activity of Alpinia (Alpinia zerumbet) leaves exposed to UV. Int Lett Nat Sci. 2016;55:25–34.  https://doi.org/10.18052/www.scipress.com/ILNS.55.25.CrossRefGoogle Scholar
  14. 14.
    Xuan TD, Teschke R. Dihydro-5,6-dehydrokavain (DDK) from Alpinia zerumbet: its isolation, synthesis, and characterization. Molecules. 2015;20(9):16306–19.  https://doi.org/10.3390/molecules200916306.CrossRefPubMedGoogle Scholar
  15. 15.
    Teschke R, Schwarzenboeck A, Frenzel C, Schulze J, Eickhoff A, Wolff A. The mystery of the Hawaii liver disease cluster in summer 2013: a pragmatic and clinical approach to solve the problem. Ann Hepatol. 2016;15:91–119. Available at: http://www.annalsofhepatology.com.mx/revista/numeros/2016/HP161-12-Mystery%20(web)%20(FF_041215V)_PROTEGIDO%20(1).pdf. Accessed 22.10.2017CrossRefPubMedGoogle Scholar
  16. 16.
    Calitz C, du Plessis L, Gouws C, Steyn D, Steenekamp J, Muller C, et al. Herbal hepatotoxicity: current status, examples, and challenges. Expert Opin Drug Metab Toxicol. 2015;11(10):1551–65.  https://doi.org/10.1517/17425255.2015.1064110.CrossRefPubMedGoogle Scholar
  17. 17.
    Brown A. Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 2 of 5 series. Food Chem Toxicol. 2017;107(Pt A):472–501.  https://doi.org/10.1016/j.fct.2016.07.001.CrossRefPubMedGoogle Scholar
  18. 18.
    Jing J, Teschke R. Traditional Chinese medicine (TCM) and herb induced liver injury: comparison with drug induced liver injury. J Clin Transl Hepatol. 2018;6(1):1–12.  https://doi.org/10.14218/JCTH.2017.00033.CrossRefGoogle Scholar
  19. 19.
    Teschke R, Wolff A, Frenzel C, Eickhoff A, Schulze J. Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders. World J Gastroenterol. 2015;21(15):4466–90.  https://doi.org/10.3748/wjg.v21.i15.4466.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Teschke R, Larrey D, Melchart D, Danan G. Traditional Chinese medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Medicines. 2016;3(3):18.  https://doi.org/10.3390/medicines3030018.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Wang R, Han D, Sun M, Teschke R, Yang SS, Mendez-Sanchez N, et al. Efficacy and safety of integration of traditional and Western medicine for the treatment of spontaneous bacterial peritonitis in liver cirrhosis: a systematic review. AME Med J. 2017;2:138.  https://doi.org/10.21037/amj.2017.08.10.CrossRefGoogle Scholar
  22. 22.
    Teschke R, Eickhoff A. Herbal hepatotoxicity in traditional and modern medicine: actual key issues and new encouraging steps. Front Pharmacol. 2015;6:72.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    WHO. Essential medicines and health products. Traditional Medicine: Definitions. Available at: http://www.who.int/medicines/areas/traditional/definitions/en/. Last accessed 27.09. 2017.
  24. 24.
    Melchart D, Hager S, Albrecht S, Dai J, Weidenhammer W, Teschke R. Herbal Traditional Chinese Medicine and suspected liver injury: a prospective study. World J Hepatol. 2017;18(9):1141–57.  https://doi.org/10.4254/wjh.v9.i29.1141.CrossRefGoogle Scholar
  25. 25.
    Teschke R, Danan G. Causality assessment in pharmacovigilance for herbal medicines. In: Barnes J, editor. Pharmacovigilance of herbal medicines: reflections, solutions and future perspectives. Berlin: Springer (Adis Books); 2017. in press.Google Scholar
  26. 26.
    Teschke R, Schulze J, Eickhoff A, Wolff A, Frenzel C. Mysterious Hawaii liver disease case—naproxen overdose as cause rather than OxyELITE pro? J Liver Clin Res. 2015;2(2):1013. Available at: http://www.jscimedcentral.com/Liver/liver-2-1013.pdf. Accessed 20.10.17Google Scholar
  27. 27.
    Teschke R, Eickhoff A, Schulze J, Wolff A, Frenzel C, Melchart D. Petadolex®, a herbal extract for migraine prophylaxis with spontaneous case reports of disputed liver injury: robust causality evaluation by RUCAM, the Roussel Uclaf Causality Assessment Method. Eur J Pharm Med Res. 2016;3(12):154–77.Google Scholar
  28. 28.
    Liu WJH. Feature article. What has been overlooked on study of Chinese Materia Medica in the West? Chin J Integr Med. 2015;21:483–99.CrossRefPubMedGoogle Scholar
  29. 29.
    Zambrone FAD, Corrêa CL, Sampaio do Amaral LM. A critical analysis of the hepatotoxicity cases described in the literature related to Herbalife products. Braz J Pharm Sci. 2015;51:785–96. Available at:  https://doi.org/10.1590/S1984-82502015000400004.
  30. 30.
    Cha JY, Khaleda L, Park HJ, Kim WY. A chaperone surveillance system in plant circadian rhythms. BMB Rep. 2017;50(5):235–6.  https://doi.org/10.5483/BMBRep.2017.50.5.064.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Elzaawely AA, Xuan TD, Tawata S. Changes in essential oils, kava pyrones and total phenolics of Alpinia zerumbet (Pers.) B. L. Burtt. & R.M. Sm. leaves exposed to copper sulphate. Environ Exp Bot. 2007b;59(3):347–53.  https://doi.org/10.1016/j.envexpbot.2006.04.007.CrossRefGoogle Scholar
  32. 32.
    Tong K, Li ZL, Sun X, Yan S, Jiang MJ, Deng MS, et al. Metabolomics approach reveals annual metabolic variation in roots of Cyathula officinalis Kuan based on gas chromatography-mass spectrum. Chin Med. 2017;12(1):12.  https://doi.org/10.1186/s13020-017-0133-1.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Lin L, Li H, Lin H, Zhang M, Qu C, Yan L, et al. A new perspective on liver injury by traditional Chinese herbs such as Polygonum multiflorum: The geographical area of harvest as an important contributory factor. Front Pharmacol. 2017. Available at:  https://doi.org/10.3389/fphar.2017.00349
  34. 34.
    Kuchta K, Schmidt M, Nahrstedt A. German Kava ban lifted by court: the alleged hepatotoxicity of Kava (Piper methysticum) as a case of ill-defined herbal drug identity, lacking quality control, and misguided regulatory politics. Planta Med. 2015;81(18):1647–53.  https://doi.org/10.1055/s-0035-1558295.CrossRefPubMedGoogle Scholar
  35. 35.
    Savage K, Stough C, Byrne GJ, Scholey A, Bousman C, Murphy J, et al. Kava for the Treatment of Generalised Anxiety Disorder (K-GAD): study protocol for a randomized controlled trial. Trials. 2015;16:493. Available at: http://www.trialsjournal.com/content/16/1/493/about CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Hamre HJ, Glockmann A, Heckenbach K, Matthes H. Use and safety of anthroposophic medicinal products: an analysis of 44,662 patients from the EvaMed Pharmacovigilance Network. Drugs Real World Outcomes. 2017;  https://doi.org/10.1007/s40801-017-0118-5.
  37. 37.
    Calahan J, Howard D, Almalki A, Gupta MP, Calderón AI. Chemical adulterants in herbal medicinal products: a review. Planta Med. 2016;82(06):505–15.  https://doi.org/10.1055/s-0042-103495.CrossRefPubMedGoogle Scholar
  38. 38.
    Gao H, Ruan JQ, Chen J, Li N, Ke CQ, Ye Y, et al. Blood pyrrole-protein adducts as diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug Des Dev Ther. 2015;9:4861–8.CrossRefGoogle Scholar
  39. 39.
    Melchart D, Hager S, Dai J, Weidenhammer W. Quality control and complication screening programme of Chinese medicinal drugs at the first German hospital of Traditional Chinese Medicine—a retrospective analysis. Forsch Komplementärmed. 2016;23(2):21–8.  https://doi.org/10.1159/000444983.Google Scholar
  40. 40.
    Zhang P, Ye Y, Yang X, Jiao Y. Systematic review on Chinese herbal medicine induced liver injury. Evid Based Complement Alternat Med. 2016:3560812.  https://doi.org/10.1155/2016/3560812.
  41. 41.
    Teschke R, Zhang L, Long H, Schwarzenboeck A, Schmidt-Taenzer W, Genthner A, et al. Traditional Chinese Medicine and herbal hepatotoxicity: a tabular compilation of reported cases. Ann Hepatol. 2015;14:7–19.CrossRefPubMedGoogle Scholar
  42. 42.
    Cho JH, Oh DS, Hong SH, Ko H, Lee NH, Park SE, et al. A nationwide study of the incidence rate of herb-induced liver injury in Korea. Arch Toxicol. 2017;  https://doi.org/10.1007/s00204-017-2007-9.
  43. 43.
    Vega M, Verma M, Beswick D, Bey S, Hossack J, Merriman N, et al. The incidence of drug- and herbal and dietary supplement-induced liver injury: preliminary findings from gastroenterologist-based surveillance in the population of the State of Delaware. Drug Saf. 2017;40(9):783–7.  https://doi.org/10.1007/s40264-017-0547-9.CrossRefPubMedGoogle Scholar
  44. 44.
    Teschke R, Eickhoff A. Suspected liver injury and the dilemma of causality. Dig Dis Sci. 2017;62(4):1095–8.  https://doi.org/10.1007/s10620-016-4442-5.CrossRefPubMedGoogle Scholar
  45. 45.
    Teschke R, Editorial DG. Drug-induced liver injury, mortality, and liver transplantation: is it reasonable to use a global introspection causality assessment? AME Med J. 2017;  https://doi.org/10.21037/amj.2017.9.05.
  46. 46.
    Teschke R, Eickhoff A, Schwarzenboeck A, Schmidt-Taenzer W, Genthner A, Frenzel C, et al. Clinical review: Herbal hepatotoxicity and the call for systematic data documentation of individual cases. J Liver Clin Res. 2015;2:1008. Available at: http://www.jscimedcentral.com/Liver/liver-2-1008.pdf Google Scholar
  47. 47.
    Teschke R, Schulze J, Eickhoff A, Danan G. Drug induced liver injury: can biomarkers assist RUCAM in causality assessment? Int J Mol Sci. 2017;18(4):803.  https://doi.org/10.3390/ijms18040803.CrossRefPubMedCentralGoogle Scholar
  48. 48.
    Zhu Y, Niu M, Chen J, Zou ZS, Ma ZJ, Liu SH, et al. Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients. J Gastroenterol Hepatol. 2016;31(8):1476–82.  https://doi.org/10.1111/jgh.13323.CrossRefPubMedGoogle Scholar
  49. 49.
    Mazzanti G, Di Soto A, Vitalone A. Hepatotoxicity of green tea: an update. Arch Toxicol. 2015;89(8):1175–91.  https://doi.org/10.1007/s00204-015-1521-x.CrossRefPubMedGoogle Scholar
  50. 50.
    Lu RJ, Zhang Y, Tang FL, Zheng ZW, Fan ZD, Zhu SM, et al. Clinical characteristics of drug-induced liver injury and related risk factors. Exp Ther Med. 2016;12(4):2606–16.  https://doi.org/10.3892/etm.2016.3627.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Teschke R, Danan G. Causality assessment methods in drug-induced liver injury. In: Drug-induced liver toxicity. Minjun Chen and Yvonne Will. Methods in pharmacology and toxicology/Y. James Kang & David C. Casey. Springer Protocols, Springer, Berlin, 2018, in press.Google Scholar
  52. 52.
    DCH T, Ng PSL, Tan SH, Lim AT, DSL T, Chan SY, et al. Drug-induced liver injury associated with complementary and alternative medicine: a review of adverse event reports in an Asian community from 2009 to 2014. BMC Complement Altern Med. 2016;16(1):192.  https://doi.org/10.1186/s12906-016-1168z.CrossRefGoogle Scholar
  53. 53.
    Lee WJ, Kim HW, Son CG. Systematic review on herb induced liver injury in Korea. Food Chem Toxicol. 2015;84:47–54.  https://doi.org/10.1016/j.fct.2015.06.004.CrossRefPubMedGoogle Scholar
  54. 54.
    Yu YC, Mao YM, Chen CW, Chen JJ, Chen J, Cong WM, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int. 2017;11(3):221–41.  https://doi.org/10.1007/s12072-017-9793-2.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Wang J, Ma Z, Niu M, Zhu Y, Liang Q, Zhao Y, et al. Evidence chain-based causality identification in herb-induced liver injury: exemplification of a well-known liver-restorative herb Polygonum multiflorum. Front Med. 2015;9(4):457–67.  https://doi.org/10.1007/s11684-015-0417-8.CrossRefPubMedGoogle Scholar
  56. 56.
    Woo HJ, Kim HY, Choi ES, Cho YH, Kim Y, Lee JH, et al. Drug-induced liver injury: a 2-year retrospective study of 1169 hospitalized patients in a single medical center. Phytomedicine. 2015;22(13):1201–5.  https://doi.org/10.1016/j.phymed.2015.10.002.CrossRefPubMedGoogle Scholar
  57. 57.
    Hayashi PH, Rockey D, Fontana RJ, Tillmann HL, Kaplowitz N, Barnhart H, et al. Death and liver transplantation within two years of onset of drug-induced liver injury. Hepatology. 2017, in press;  https://doi.org/10.1002/hep.29283.
  58. 58.
    Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. Liver injury from herbal and dietary supplements. Hepatology. 2017;65(1):1363–73.  https://doi.org/10.1002/hep.28813.CrossRefGoogle Scholar
  59. 59.
    Wong LL, Lacar L, Roytman M, Orloff SL. Urgent liver transplantation for dietary supplements: an under-recognized problem. Transplant Proc. 2017;49(2):322–5.  https://doi.org/10.1016/j.transproceed.2016.11.041.CrossRefPubMedGoogle Scholar
  60. 60.
    Cholankeril G, Wong RJ, Hu M, Perumpail RB, Yoo ER, Puri P, et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci. 2017;62(10):2915–22.  https://doi.org/10.1007/s10620-017-4684-x.CrossRefPubMedGoogle Scholar
  61. 61.
    Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wimmer M. Fatty liver disease—meta-analytic assessment of prevalence assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84.  https://doi.org/10.1002/hep.28431.CrossRefPubMedGoogle Scholar
  62. 62.
    Hayashi PH. Drug-induced liver injury network causality assessment: criteria and experience in the United States. Int J Mol Sci. 2016;17(2):201.  https://doi.org/10.3390/ijms17020201.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Teschke R, Xuan TD. Viewpoint: a contributory role of Shell ginger (Alpinia zerumbet) and human longevity of Okinawa in Japan? Nutrients. 2018;10:166.  https://doi.org/10.3390/nu10020166.CrossRefGoogle Scholar
  64. 64.
    Marseglia L, Manti S, D’Angelo G, Nicotera A, Parisi E, Di Rosa G, et al. Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci. 2015;16(1):378–400.  https://doi.org/10.3390/ijms16010378.Google Scholar
  65. 65.
    Teschke R, Danan G. Review article: Diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf. 2016;39(8):729–44.  https://doi.org/10.1007/s40264-016-0423-z.CrossRefPubMedGoogle Scholar
  66. 66.
    Teschke R, Danan G. Drug-induced liver injury: is chronic liver disease a risk factor and a clinical issue? Expert Opin Drug Metab Toxicol. 2017;13(4):425–38.  https://doi.org/10.1080/17425255.2017.1252749.CrossRefPubMedGoogle Scholar
  67. 67.
    Centers for Disease Control and Prevention. Adult obesity causes and consequences. Available at: https://www.cdc.gov/obesity/adult/causes.html.
  68. 68.
    Ogden CL, Carroll MD, Fryar CD, Flegal KM. Prevalence of obesity among adults and youth: US, 2011–2014. NCHS Data Brief. 2015;219:1–8.Google Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Rolf Teschke
    • 1
  • Axel Eickhoff
    • 1
  • Albrecht Wolff
    • 2
  • Tran Dang Xuan
    • 3
  1. 1.Department of Internal Medicine II, Division of Gastroenterology and Hepatology, Klinikum Hanau, Teaching Hospital of the Medical FacultyGoethe University Frankfurt/MainHanauGermany
  2. 2.Department of MedicineGeorg August University GöttingenGöttingenGermany
  3. 3.Division of Development Technology, Graduate School for International Development and Cooperation (IDEC)Hiroshima UniversityHigashi HiroshimaJapan

Personalised recommendations